Search in:

Advanced search

Expert Opinion on Drug Safety Volume 7, 2008 - Issue 6

Submit an article Journal homepage

467

Views

CrossRef citations to date

Altmetric

Review

Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality

Evangelos N Liberopoulos Lecturer in Internal Medicine University of Ioannina, Medical School, Department of Internal Medicine, Ioannina, Greece

Matilda Florentin Senior House Officer University of Ioannina, Medical School, Department of Internal Medicine, Ioannina, Greece

Dimitri P Mikhailidis Reader and Honorary Consultant University College London, Royal Free Hospital Campus, Department of Clinical Biochemistry (Vascular Disease Prevention clinics), London, UK

Moses S Elisaf Professor of Internal Medicine University of Ioannina, Medical School, Department of Internal Medicine, Ioannina 45 110, Greece +30 26510 97509; +30 26510 97016; [email protected]

, MD FASA FRSH

Pages 717-725 | Published online: 04 Nov 2008

Cite this article
https://doi.org/10.1517/14740330802396984

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

World Health Organization. World health report [online]. Available from: http://www.who.int/whosis/en/index.html [Last assessed 5 August 2008]
Google Scholar
Wood D. Established and emerging cardiovascular risk factors. Am Heart J 2001;141:S49-57
PubMed Web of Science ®Google Scholar
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
PubMed Web of Science ®Google Scholar
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64
PubMed Web of Science ®Google Scholar
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427
PubMed Web of Science ®Google Scholar
Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13
PubMed Web of Science ®Google Scholar
Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86
PubMed Web of Science ®Google Scholar
Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31
PubMed Web of Science ®Google Scholar
Berg JS, Dischler J, Wagner DJ, et al. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27:S1-24
PubMed Web of Science ®Google Scholar
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11
PubMed Web of Science ®Google Scholar
Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62
PubMed Web of Science ®Google Scholar
The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997;18:1718-24
PubMed Web of Science ®Google Scholar
Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-4
PubMed Web of Science ®Google Scholar
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
PubMed Web of Science ®Google Scholar
Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008;62:88-96
PubMed Web of Science ®Google Scholar
Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007;195:7-16
PubMed Web of Science ®Google Scholar
Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008;24:995-1009
PubMed Web of Science ®Google Scholar
Serruys PW, De Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22
PubMed Web of Science ®Google Scholar
Lesaffre E, Kocmanova D, Lemos PA, et al. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003;25:2431-47
PubMed Web of Science ®Google Scholar
Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698-708
PubMed Web of Science ®Google Scholar
Task Force Report. Prevention of coronary heart disease in clinical practice. Available from: www.escardio.org [Last assessed 5 August 2008]
Google Scholar
Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
PubMed Web of Science ®Google Scholar
Hippisley Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003;326:689
PubMed Web of Science ®Google Scholar
Kindermann M, Adam O, Werner N, Bohm M. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol 2007;96:767-86
PubMed Web of Science ®Google Scholar
Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease–related events. J Cardiovasc Pharmacol Ther 2001;6:129-35
PubMedGoogle Scholar
Hilleman DE, Monaghan MS, Ashby CL, et al. Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease. Pharmacotherapy 2001;21:1415-21
PubMed Web of Science ®Google Scholar
Van Ganse E, Souchet T, Laforest L, et al. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis 2006;185:58-64
PubMed Web of Science ®Google Scholar
Euro Heart Survey-ESC Congress; September 2007 Vienna. Available from: http://www.escardio.org [Last assessed 5 August 2008]
Google Scholar
Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59:564-73
PubMed Web of Science ®Google Scholar
Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52
PubMed Web of Science ®Google Scholar
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
PubMed Web of Science ®Google Scholar
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
PubMed Web of Science ®Google Scholar
Daly C, Clemens F, Lopez Sendon JL, et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006;27:1298-304
PubMed Web of Science ®Google Scholar
Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69:904-10
PubMed Web of Science ®Google Scholar
Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002;91:173-9
PubMed Web of Science ®Google Scholar
Li JJ, Li YS, Chen J, Yang JQ. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses 2006;66:1199-204
PubMed Web of Science ®Google Scholar
Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998;352:1830-1
PubMed Web of Science ®Google Scholar
Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000;102:3104-10
PubMed Web of Science ®Google Scholar
Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-7
PubMed Web of Science ®Google Scholar
LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6
PubMed Web of Science ®Google Scholar
Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7
PubMed Web of Science ®Google Scholar
Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-86
PubMed Web of Science ®Google Scholar
Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-33
PubMed Web of Science ®Google Scholar
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
PubMed Web of Science ®Google Scholar
Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP. Early statin therapy in patients with acute coronary syndrome. Hellenic J Cardiol 2005;46:5-8
PubMedGoogle Scholar
Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52
PubMed Web of Science ®Google Scholar
Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med 2004;164:2162-8
PubMed Web of Science ®Google Scholar
Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117:1028-36
PubMed Web of Science ®Google Scholar
Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-7
PubMed Web of Science ®Google Scholar
Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61
PubMed Web of Science ®Google Scholar
Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
PubMed Web of Science ®Google Scholar
Burke LE, Ockene IS. Compliance in healthcare and research. Armonk, NY: Futura Publishing Co., Inc.; 2001
Google Scholar
Rollnick SMP, Butler C. Health behavior change: a guide for practicioners. New York, NY: Churchill Livingstone; 1999
Google Scholar
The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789-99
PubMed Web of Science ®Google Scholar
Hudson M, Rahme E, Richard H, Pilote L. Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007;153:59-65
PubMed Web of Science ®Google Scholar
Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, et al. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005;21:231-44
PubMed Web of Science ®Google Scholar
Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483-5
PubMed Web of Science ®Google Scholar
Kettawan A, Takahashi T, Kongkachuichai R, et al. Protective effects of coenzyme q(10) on decreased oxidative stress resistance induced by simvastatin. J Clin Biochem Nutr 2007;40:194-202
PubMed Web of Science ®Google Scholar
Zhipeng W, Mingkai L, Shuyu C, et al. Toxicity of coenzyme Q10: a report of 90-day repeated dose toxicity study in rats. J Toxicol Sci 2007;32:505-14
PubMedGoogle Scholar
Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q10; supplementation on simvastatin-induced myalgia. Am J Cardiol 2007;100:1400-3
PubMed Web of Science ®Google Scholar
Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, Liapis CD. Lipid management and peripheral arterial disease. Curr Drug Targets 2007;8:561-70
PubMed Web of Science ®Google Scholar
Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333-5
PubMed Web of Science ®Google Scholar
Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
PubMed Web of Science ®Google Scholar
Fonarow GC, Gawlinski A, Watson K. In-hospital Initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes: the University of California-Los Angeles, Cardiovascular Hospitalization Atherosclerosis Management Program. Crit Pathw Cardiol 2003;2:61-70
PubMedGoogle Scholar
Daugherty SL, Ho PM, Spertus JA, et al. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch Intern Med 2008;168:485-91
PubMed Web of Science ®Google Scholar
Smith DH, Kramer JM, Perrin N, et al. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med 2008;168:477-83
PubMed Web of Science ®Google Scholar
Schoenthaler A, Ogedegbe G. Patients perceptions of electronic monitoring devices affect medication adherence in hypertensive African Americans. Ann Pharmacother 2008;42:647-52
PubMed Web of Science ®Google Scholar
Batal HA, Krantz MJ, Dale RA, et al. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res 2007;7:175
PubMed Web of Science ®Google Scholar
Athyros VG, Tziomalos K, Mikhailidis DP, et al. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother 2007;8:2267-77
PubMed Web of Science ®Google Scholar
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9
PubMed Web of Science ®Google Scholar
Shalansky SJ, Levy AR. Effect of number of medications on cardiovascular therapy adherence. Ann Pharmacother 2002;36:1532-9
PubMed Web of Science ®Google Scholar
Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006;27:1651-6
PubMed Web of Science ®Google Scholar
Williams B, Shaw A, Durrant R, et al. Patient perspectives on multiple medications versus combined pills: a qualitative study. QJM 2005;98:885-93
PubMed Web of Science ®Google Scholar
Stewart D, John D, Cunningham S, et al. A comparison of community pharmacists' views of over-the-counter omeprazole and simvastatin. Pharmacoepidemiol Drug Saf 2007;16:1290-7
PubMed Web of Science ®Google Scholar
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
PubMed Web of Science ®Google Scholar
Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997;102:43-9
PubMedGoogle Scholar
Schlenk EABL, Rand C. Behavioral strategies to improve medication-taking compliance. In: Burke LE, Ockene IS, editors, Compliance in healthcare and research. Armonk, NY: Futura Publishing Co.; 2001. p. 57-70
Google Scholar
Goldman DP, Joyce GF, Karaca Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 2006;12:21-8
PubMed Web of Science ®Google Scholar
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
PubMed Web of Science ®Google Scholar
Federman AD, Adams AS, Ross Degnan D, et al. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA 2001;286:1732-9
PubMed Web of Science ®Google Scholar
Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-9
PubMed Web of Science ®Google Scholar
Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care 2005;43:951-9
PubMed Web of Science ®Google Scholar
Tarn DM, Paterniti DA, Kravitz RL, et al. How much time does it take to prescribe a new medication? Patient Educ Couns 2008;77:219-26
Google Scholar
Joosten EA, DeFuentes Merillas L, de Weert GH, et al. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 2008;77:219-26
PubMed Web of Science ®Google Scholar
Stilley CS, Sereika S, Muldoon MF, et al. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-24
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date